Fostering Pharmaceutical Trade in India and China: An Empirical Study

Sami, Shaista

doi:10.5148/tncr.2014.6404

Cited by 5 publications

(5 citation statements)

References 7 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A provisional lawsuit requests that the court render a decision containing an order regarding temporary action before a final decision is rendered. The objective is to avoid ongoing loss or suffering to the plaintiff's self and interests during the investigation process of the case until the verdict has permanent legal force (Sami, 2014). As a party who feels aggrieved due to the violation, the plaintiff can submit to the Commercial Court to issue a Provisional Determination and file compensation to the defendant when the lawsuit begins to be examined and tried before the Commercial Court.…”

Section: Repressive Efforts To Protect Trade Secret Law In the Pharmaceutical Sectormentioning

confidence: 99%

“…Protection of trade secrets in the pharmaceutical sector is one way to overcome theft and counterfeiting of various medicinal products in Indonesia (Sami, 2014). Protection accompanied by adequate law enforcement against criminal acts of trade secrets in the pharmaceutical sector is expected to positively impact the pharmaceutical industry in Indonesia through fair business competition between business actors and guarantee the quality of officially registered products (Grabmair, 2017).…”

Section: Repressive Efforts To Protect Trade Secret Law In the Pharmaceutical Sectormentioning

confidence: 99%

See 1 more Smart Citation

normative structure of Indonesian pharmacy trade secret law

Noerhadi

2020

lingcure

View full text Add to dashboard Cite

This article aims to analyze the normative structure of Indonesia's trade secret protection law in the pharmaceutical sector. The analysis is carried out through two prisms: the different intellectual approaches to the judicial review law: the 'basic approach' and the 'legal approach.' Various trade secret crimes in the pharmaceutical sector, such as theft of prescription drugs and drug counterfeiting, continue to increase. We explore developments from both approaches and trace contemporary developments from the approach to law on trade secrets. We then reflect on how each response to two central legitimacy issues should provide legal protection for every owner of the trade secret in the pharmaceutical sector and the public who are victims or perpetrators of criminal trade secrets in the pharmaceutical sector.

show abstract

Section: Repressive Efforts To Protect Trade Secret Law In the Pharmaceutical Sectormentioning

confidence: 99%

Section: Repressive Efforts To Protect Trade Secret Law In the Pharmaceutical Sectormentioning

confidence: 99%

normative structure of Indonesian pharmacy trade secret law

Noerhadi

2020

lingcure

View full text Add to dashboard Cite

show abstract

“…India, a leading player in the pharmaceutical sector (IBEF, 2022; Sami, 2014; Sharma et al. , 2022), has been considered the pharmacy of the world due to its ability to produce and distribute cost-effective high quality generic drugs to the world (Avhad, 2020).…”

Section: Introductionmentioning

confidence: 99%

“…India, a leading player in the pharmaceutical sector (IBEF, 2022;Sami, 2014;Sharma et al, 2022), has been considered the pharmacy of the world due to its ability to produce and distribute cost-effective high quality generic drugs to the world (Avhad, 2020). However, the risks posed to the pharmaceutical industry worldwide (as mentioned above) also affect the Indian pharmaceutical industry.…”

Section: Introductionmentioning

confidence: 99%

Analyzing pharmaceutical industry risks under uncertainty for performance improvement: an Indian scenario

Sharma,

Kumar,

Arora

2023

BPMJ

View full text Add to dashboard Cite

PurposeThe pharmaceutical industry faces multiple risks that adversely affect its performance. Within these risks, some dependencies have been observed, which help in streamlining the mitigation efforts. Therefore, the present work identifies and categorizes various risks/sub-risks in cause–effect groups, considering uncertainty in the decision-making process.Design/methodology/approachAn extensive literature review and experts' opinions were utilized to identify and finalize the risks faced by the pharmaceutical industry. For further analysis, data collection was done using a questionnaire focusing on finalized risks. Based on the data, the causal relation under uncertainty between various risks/sub-risks was identified using a multi-criteria decision making (MCDM) technique, i.e. intuitionistic fuzzy DEMATEL, in a pairwise manner.FindingsThe results show that the three most prominent risk categories are operational, demand/customer/market and financial. Also, out of the seven main risks, only supplier and operational are categorized within the effect group and the rest, i.e. financial, demand, logistics, political and technology within the cause group. The sub-risks within each category have also been categorized into cause–effect groups. The mitigation of cause group risks will help in economize the financial resources and improve the performance and resilience of the industry.Originality/valueThere is insufficient research on identifying the causality among the pharmaceutical industry risks. Additionally, an extensive discussion on the identified cause–effect groups is also missing in the literature. Therefore, in this work, efforts have been made to determine the prominent risks for the Indian pharmaceutical industry that will be helpful for channelizing the resources to mitigate risks for a resilient industry.

show abstract

“…In India, pharmaceutical exports have been growing at a steeply increasing pace, while China saw gradual growth. India has traditionally been oriented towards the domestic market as well as the less regulated markets of Africa, Asia, and Latin America, while in China the policy focus is placed on transforming the pharma industry from a generic drug orientation towards an innovation-driven drug production and trade (Sami, 2014). A study on US biopharmaceutical competitiveness revealed that foreign price controls inflated the US trade deficit, which appeared to be about two-thirds larger than it would have been without price differences (Ezell, 2020, p. 15).…”

mentioning

confidence: 99%